{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:17:15Z","timestamp":1787815035322,"version":"build-2784847793"},"reference-count":59,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical &amp;amp; Translational All"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Lanadelumab has been approved for hereditary angioedema (HAE) long\u2010term prophylaxis since 2018. The Phase 4, prospective ENABLE Study (NCT04130191) evaluated the long\u2010term effectiveness and safety of lanadelumab in clinical practice across Europe and the Middle East.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with HAE aged \u2265\u00a012\u00a0years initiating lanadelumab treatment (300\u00a0mg every 2\u00a0weeks) per approved product labeling were recruited from Austria, Germany, Israel, Italy, Kuwait, Spain, and Switzerland and followed for up to 36\u00a0months (\u00b1\u00a030\u00a0days). The primary objective was to evaluate lanadelumab effectiveness for HAE attack prevention. Safety and patient\u2010reported health\u2010related quality of life (HRQoL) were also evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Outcomes were analyzed in 138 patients (mean [range] age: 41.0 [14\u201379] years; 62.3% female; 92.0% HAE\u2010C1INH\u2010Type1), of whom &gt;\u00a060% extended dosing intervals by Month 12. Over a mean\u00a0\u00b1\u00a0SD treatment duration of 28.6\u00a0\u00b1\u00a09.8\u00a0months, mean\u00a0\u00b1\u00a0SD patient\u2010reported HAE attack rate decreased from 3.88\u00a0\u00b1\u00a03.43 attacks\/month pre\u2010lanadelumab to 0.30\u00a0\u00b1\u00a00.53 attacks\/month (mean decrease, 84% [median 96%]). The incidence\u2010rate ratio was 0.07 (95% CI: 0.06\u20130.10), reflecting a 93% reduction from modeled pre\u2010lanadelumab rates. Overall, 95\/138 patients reported treatment\u2010emergent adverse events (TEAEs); most were unrelated to lanadelumab (82.3%). Of the 17.7% of TEAEs considered treatment\u2010related, injection\u2010site reactions, headache, fatigue, and asthenia occurred in &gt;\u00a01 patient. Before lanadelumab initiation, most patients reported moderate\u2010to\u2010large HRQoL impairments; clinically meaningful improvements were observed 1\u00a0month after lanadelumab initiation and sustained throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Real\u2010world data from ENABLE demonstrated long\u2010term effectiveness of lanadelumab in patients with HAE aged \u2265\u00a012\u00a0years and a safety profile consistent with previous clinical studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/clt2.70190","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T05:27:30Z","timestamp":1786080450000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained Effectiveness of Lanadelumab in Preventing Hereditary Angioedema Attacks: The ENABLE Study"],"prefix":"10.1002","volume":"16","author":[{"given":"Andrea","family":"Zanichelli","sequence":"first","affiliation":[{"name":"Operative Unit of Medicine Angioedema Center IRCCS Policlinico San Donato, San Donato Milanese  Milan Italy"},{"name":"Dipartimento di Scienze Biomediche per la Salute University of Milan  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter A.","family":"Wuillemin","sequence":"additional","affiliation":[{"name":"Luzerner Kantonsspital Lucerne and University of Berne  Berne Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9218-5468","authenticated-orcid":false,"given":"Markus","family":"Magerl","sequence":"additional","affiliation":[{"name":"Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin (corporate Member of Freie Universit\u00e4t Berlin and Humboldt\u2010Universit\u00e4t zu Berlin)  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP IA  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7674-1804","authenticated-orcid":false,"given":"Andreas","family":"Recke","sequence":"additional","affiliation":[{"name":"University of L\u00fcbeck  L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Cancian","sequence":"additional","affiliation":[{"name":"University Hospital of Padua  Padua Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel","family":"Ayg\u00f6ren\u2010P\u00fcrs\u00fcn","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt Goethe University Frankfurt  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ram\u00f3n Lleonart","family":"Bellfill","sequence":"additional","affiliation":[{"name":"Allergology Department Hospital Universitari de Bellvitge Institut de Recerca IDIBELL L'Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aharon","family":"Kessel","sequence":"additional","affiliation":[{"name":"Bnai Zion Medical Centre Technion Faculty of Medicine  Haifa Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8238-2561","authenticated-orcid":false,"given":"Tamar","family":"Kinaciyan","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical University of Vienna  Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lochbaum","sequence":"additional","affiliation":[{"name":"Ulm University Medical Center  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Al\u2010Ahmad","sequence":"additional","affiliation":[{"name":"Microbiology Department College of Medicine Kuwait University  Kuwait City Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irmgard","family":"Andresen","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International AG  Zurich Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Watt","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Khutoryansky","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1245-2401","authenticated-orcid":false,"given":"Daniel N.","family":"Castaner","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas Inc.  Lexington Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Martinez\u2010Saguer","sequence":"additional","affiliation":[{"name":"HZRM Hemophilia Center Rhine Main  Frankfurt\/Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15214"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.05.055"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00212"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2010.31.3394"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010021\u201001717\u20104"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/pai.14268"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010024\u201003265\u2010z"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.08.046"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2026.101335"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2023.09.039"},{"key":"e_1_2_10_12_1","volume-title":"Takeda Pharmaceuticals","year":"2025"},{"key":"e_1_2_10_13_1","unstructured":"European Medcines Agency \u201cTAKHZYRO [Summary of Product Characteristics] \u201d (2024) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/takhzyro\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_14_1","unstructured":"Swissmedic. Takeda Pharmaceutical Company Limited TAKHZYRO\u00aeArzneimittelinformation\/Information sur le m\u00e9dicament (2025) https:\/\/swissmedicinfo.ch\/showText.aspx?textType=FI&lang=EN&authNr=68178&supportMultipleResults=1."},{"key":"e_1_2_10_15_1","article-title":"Takeda Pharmaceutical Company Limited. Highlights of Prescribing Information","author":"U. S. Food and Drug Administration","year":"2025","journal-title":"Takhzyro\u2122 (lanadelumab\u2010flyo) injection, for subcutaneous use"},{"key":"e_1_2_10_16_1","unstructured":"European Medicines Agency Takeda Pharmaceutical Company Limited. TAKHZYRO\u00ae(lanadelumab\u2010flyo) Summary of Product Characteristics (2025) https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/takhzyro\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_10_17_1","unstructured":"Electronic Medicine Compendium \u201cTAKHZYRO\u00ae300 Mg Solution for Injection in Pre\u2010filled Syringe Summary of Product Characteristics \u201d (2024) https:\/\/www.medicines.org.uk\/emc\/product\/12051\/smpc."},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223\u2010025\u201000999\u20108"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.70207"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1605767"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.16773"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.16909"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15011"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.09.009"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801\u2010025\u201000505\u2010x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100664"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000541242"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110542"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1405317"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.04.072"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.15620"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.2020.5269"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13223\u2010022\u201000664\u20104"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010025\u201003226\u20103"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2024.12.008"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14144"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.02.038"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12007"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.12900"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1989.00520460115022"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/occmed\/kqu024"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u20100447.1983.tb09716.x"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524\u20104733.2006.00101.x"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053\u2010199304050\u201000006"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477\u20107525\u20107\u201036"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12295"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/31.11.1601"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2019.05.003"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010021\u201008855\u20104"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00350\u20101"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.02.018"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010025\u201004134\u2010z"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13601\u2010018\u20100229\u20104"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.10.011"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2023.03.028"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14680"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016\u2010021\u201008839\u20104"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010022\u201002360\u20103"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14632"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14527"}],"container-title":["Clinical and Translational Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70190","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clt2.70190","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clt2.70190","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T06:21:51Z","timestamp":1787811711000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clt2.70190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":59,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/clt2.70190"],"URL":"https:\/\/doi.org\/10.1002\/clt2.70190","archive":["Portico"],"relation":{},"ISSN":["2045-7022","2045-7022"],"issn-type":[{"value":"2045-7022","type":"print"},{"value":"2045-7022","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"e70190"}}